Efficacy of SGLT2 Inhibitors in Recently Hospitalized Heart Failure Patients

An exploratory, prespecified pooled analysis of the DELIVER and EMPEROR-Preserved trials, published in 2026, investigates SGLT2 inhibitor efficacy in high-risk heart failure patients. The analysis, authored by Xiaomin Xue, pools data from two major trials to examine cardiovascular outcomes in patients with preserved ejection fraction and a recent heart failure hospitalization. It defines two high-risk subgroups based on hospitalization recency (within 30 days or 12 months).

Use Cases

• Estimating treatment effect sizes for SGLT2 inhibitors based on pooled trial data.
• Generating hypotheses for future dedicated studies based on exploratory findings.
• Comparing cardiovascular outcomes across different definitions of 'recent' hospitalization.
• Assessing the safety profile of SGLT2 inhibitors in a specific, high-risk patient population.

Strengths

• Analysis is prespecified and pools data from two major, named clinical trials (DELIVER and EMPEROR-Preserved).
• Provides precise hazard ratios (HR: 0.78 and 0.73) with 95% confidence intervals for two distinct high-risk subgroups.
• Explicitly reports subgroup sizes (n=654 for the 'strict' group, n=1,369 for the 'broad' group).

Limitations

• The analysis is exploratory and hypothesis-generating, limiting definitive conclusions.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare

Collection Method

Prespecified pooled analysis of two randomized controlled trials.

Freshness

Last updated 2026-05-12 05:42:31; freshness should be verified.